Three-pronged treatment well tolerated in patients with indolent lymphomas

Forman, Stephen; Adams, Stacey L.; Dickinson, Cara; Levitan, Dave; Shafer, Emily
April 2008
Hem/Onc Today;4/10/2008, Vol. 9 Issue 6, p39
This article focuses on a study published in a 2008 issue of "Leukemia & Lymphoma" that examined the effectiveness of fludarabine, mitoxantrone and rituximab as a three-pronged treatment regimen for patients with indolent lymphomas. Particular focus is given to the dosing regimen received by the patients. According to results of the study, majority of the patients were alive and disease-free after 39 months of treatment. It also found that patients with marginal zone lymphoma had higher complete response rates than those with indolent lymphomas.


Related Articles

  • High-dose mitoxantrone + melphalan (MITO/L-PAM) as conditioning regimen supported by peripheral blood progenitor cell (PBPC) autograft in 113 lymphoma patients: high tolerability with reversible cardiotoxicity. Tarella, C; Zallio, F; Caracciolo, D; Cuttica, A; Corradini, P; Gavarotti, P; Ladetto, M; Podio, V; Sargiotto, A; Rossi, G; Gianni, A M; Pileri, A // Leukemia (08876924);Feb2001, Vol. 15 Issue 2, p256 

    Hematological and extrahematological toxicity of high-dose (hd) mitoxantrone (MITO) and melphalan (L-PAM) as conditioning regimen prior to peripheral blood progenitor cell (PBPC) autograft was evaluated in 113 lymphoma patients (87 at disease onset). Autograft was the final part of a...

  • A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by 90Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma. Zinzani, P. L.; Tani, M.; Pulsoni, A.; De Renzo, A.; Stefoni, V.; Broccoli, A.; Montini, G. C.; Fina, M.; Pellegrini, C.; Gandolfi, L.; Cavalieri, E.; Torelli, F.; Scopinaro, F.; Argnani, L.; Quirini, F.; Derenzini, E.; Rossi, M.; Pileri, S.; Fanti, S.; Baccarani, M. // Annals of Oncology;Feb2012, Vol. 23 Issue 2, p415 

    Background: A prospective, single-arm, open-label, multicenter, nonrandomised phase II trial to evaluate efficacy and safety of short fludarabine, mitoxantrone, and rituximab (FMR) induction followed by radioimmunotherapy, in untreated, intermediate/high-risk follicular non-Hodgkin’s...

  • Successful treatment of lymphoma with fludarabine combined with rituximab after immune thrombocytopenia induced by fludarabine. Tsutsumi, Yutaka; Kanamori, Hiroe; Minami, Hiina; Musashi, Mio; Fukushima, Arata; Ehira, Nobuyuki; Yamato, Hiroaki; Obara, Shinji; Ogura, Nobutaka; Tanaka, Junji; Asaka, Masahiro; Imamura, Masahiro; Masauzi, Nobuo // Annals of Hematology;Apr2005, Vol. 84 Issue 4, p269 

    A 47-year-old man was diagnosed with non-Hodgkin’s lymphoma (NHL) follicular B-cell type (stage IVB). Although partial remission was observed after the administration of several combination chemotherapeutic agents, no more improvement was observed. After we finished the FND (fludarabine,...

  • Antineoplastics.  // Reactions Weekly;6/20/2009, Issue 1257, p8 

    The article describes the case of a 64-year-old woman who developed fatal progressive multifocal leukoencephalopathy while under fludarabine, rituximab, mitoxantrone and cyclophosphamide treatment regimen for chronic lymphocytic leukaemia (CLL). The patient was placed under the regimen after...

  • Combination therapy effective in NHL.  // Hem/Onc Today;5/10/2008, Vol. 9 Issue 8, p28 

    The article reports on the affectivity of combination of fludarabine and mitoxantrone plus 90Y-ibritumomab tiuxetan on non-Hodgkin's lymphoma (NHL). It states NHL patients may benefit from this combination therapy. Researchers from Italy conducted an examination on the safety and efficacy of...

  • A phase II study of intensive chemotherapy with fludarabine, cytarabine, and mitoxantrone in P glycoprotein-negative high-risk myelodysplastic syndromes. Prébet, Thomas; Ducastelle, Sophie; Debotton, Stephan; Stamatoullas, Aspasia; Deconinck, Eric; Fruchart, Christophe; Gratecos, Nicole; Ifrah, Norbert; Dreyfus, François; Fenaux, Pierre; Wattel, Eric // Hematology Journal;2004, Vol. 5 Issue 3, p209 

    Since leukemic cells primed by exposure to fludarabine exhibit enhanced accumulation of cytarabine triphosphate (the cytotoxic nucleotide of cytarabine), especially with continuous cytarabine (AraC) infusion, a phase II trial was designed to explore the feasibility and efficacy of a combination...

  • Impact of dose intensity on outcome of fludarabine, cyclophosphamide, and rituximab regimen given in the first-line therapy for chronic lymphocytic leukemia. Fox, Christopher // Current Medical Literature: Leukemia & Lymphoma;2013, Vol. 21 Issue 2, p53 

    The article discusses the impact of dose intensity on fludarabine, cyclophosphamide and rituximab (FCR) regimen outcome in chronic lymphocytic leukemia patients. It references the study "Impact of Dose Intensity on Outcome of fludarabine, cyclophosphamide and rituximab Regimen Given in the...

  • Cell Therapeutics's combination therapy found effective against lymphoma.  // PharmaWatch: Biotechnology;May2008, Vol. 7 Issue 5, p7 

    The article reports that patients with previously untreated follicular non-Hodgkin's lymphoma treated with fludarabine and mitoxantrone, followed by Zevallin, achieved 96 percent complete remission in a study conducted by Cell Therapeutics Inc. It underscores the potential use of...

  • Pharmacotherapy Update: Fludarabine in the Treatment of Non-Hodgkin's Lymphoma. Shvidel, Lev; Cohn, Mirel; Sigler, Erica // Clinical Medicine: Therapeutics;2009, Issue 1, p359 

    Fludarabine, a purine nucleoside analogue, is considered as the most active drug in chronic lymphocytic leukemia. This review summarizes current knowledge concerning the mechanism of action, pharmacological properties, clinical activity and toxicity of fl udarabine in the treatment of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics